However, anti-PD-1/PD-L1 or anti-CTLA4 was mainly used in triple-negative breast cancer (TNBC) (54–56); thus, we would choose TNBC patients in further studies. This evidence concerns the gene CD274 and triple-negative breast carcinoma.